Pom/dex (Pomalidomide plus low dose Dexamethasone) clinical trials

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

This study compares a new treatment, Belantamab Mafodotin, with a common combination treatment (Pomalidomide and Dexamethasone) for Multiple Myeloma that has returned or not responded well to past treatments. It aims to see which treatment works better and is safer.